Informazioni sul prodotto
- 3-[[3-[4-[[3-(β-D-Glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]-3-methylphenoxy]propyl]amino]propanamide
- Propanamide, 3-[[3-[4-[[3-(β-D-glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]-3-methylphenoxy]propyl]amino]-
- KGA 2727
KGA-2727 is a novel, orally administered, non-peptidic, small molecule antidiabetic agent that increases glucose uptake in skeletal muscle cells by inhibiting the sodium-dependent glucose transporter type 2 (SGLT2) and the accompanying sodium-glucose cotransporter. KGA-2727 has been shown to lower blood pressure and increase insulin sensitivity in diabetic mice. Chronic treatment with KGA-2727 has been shown to increase insulin sensitivity in wild-type mice without any adverse effects. This drug also lowers blood sugar levels in patients with type 2 diabetes.
Proprietà chimiche
Richiesta tecnica su: 3D-RBB84236 KGA-2727
Se si desidera richiedere un preventivo o effettuare un ordine, si prega invece di aggiungere i prodotti desiderati al carrello e poi richiedere un preventivo o un ordine dal carrello. È più veloce, più economico, e potrà beneficiare degli sconti disponibili e di altri vantaggi.
